
November 27, 2017 - By Louis Casey
Capital Guardian Trust Company decreased its stake in Jd.Com Inc A Adr (JD) by 12.74% based on its latest 2017Q2 regulatory filing with the SEC. Capital Guardian Trust Company sold 223,156 shares as the company’s stock rose 37.55% with the market. The institutional investor held 1.53 million shares of the consumer services company at the end of 2017Q2, valued at $59.94M, down from 1.75 million at the end of the previous reported quarter. Capital Guardian Trust Company who had been investing in Jd.Com Inc A Adr for a number of months, seems to be less bullish one the $55.81 billion market cap company. The stock declined 0.64% or $0.25 reaching $38.96 per share. About 29,401 shares traded. JD.Com Inc(ADR) (NASDAQ:JD) has risen 77.67% since November 27, 2016 and is uptrending. It has outperformed by 60.97% the S&P500.Temasek Holdings Private Ltd decreased its stake in Portola Pharmaceuticals Inc (PTLA) by 25.82% based on its latest 2017Q2 regulatory filing with the SEC. Temasek Holdings Private Ltd sold 1.70 million shares as the company’s stock rose 22.73% with the market. The institutional investor held 4.88 million shares of the health care company at the end of 2017Q2, valued at $274.31 million, down from 6.58 million at the end of the previous reported quarter. Temasek Holdings Private Ltd who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be less bullish one the $3.30B market cap company. It closed at $50.55 lastly. It is down 51.17% since November 27, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.Capital Guardian Trust Company, which manages about $5.45 billion US Long portfolio, upped its stake in Credicorp Ltd (NYSE:BAP) by 41,900 shares to 131,700 shares, valued at $23.63M in 2017Q2, according to the filing. It also increased its holding in Petroleo Brasileiro Pn Adr (Petrobras) by 55,400 shares in the quarter, for a total of 1.18 million shares, and has risen its stake in Williams Companies Inc (The) (NYSE:WMB). More notable recent JD.Com Inc(ADR) (NASDAQ:JD) news were published by: Investorplace.com which released: “JD.Com Inc(ADR) Stock Is Red-Hot After Singles Day Success” on November 13, 2017, also Investorplace.com with their article: “Why You Should Buy JD.Com Inc(ADR) Stock Immediately!” published on November 09, 2017, Nasdaq.com published: “Earnings Reaction History: JD.COM INC-ADR, 36.4% Follow-Through Indicator, 4.7 …” on November 13, 2017. More interesting news about JD.Com Inc(ADR) (NASDAQ:JD) were released by: Investorplace.com and their article: “JD.Com Inc (ADR) Stock Is on the Verge of a Correction” published on October 31, 2017 as well as Investorplace.com‘s news article titled: “Monday’s Vital Data: Nvidia Corporation (NVDA), JD.Com Inc (ADR) (JD) and …” with publication date: November 13, 2017.Among 21 analysts covering JD.com (NASDAQ:JD), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. JD.com had 41 analyst reports since August 4, 2015 according to SRatingsIntel. UBS upgraded JD.Com Inc(ADR) (NASDAQ:JD) on Monday, October 30 to “Buy” rating. The rating was initiated by HSBC on Tuesday, November 10 with “Buy”. Morgan Stanley downgraded the stock to “Overweight” rating in Monday, August 10 report. Nomura upgraded the shares of JD in report on Friday, January 22 to “Buy” rating. Morgan Stanley downgraded JD.Com Inc(ADR) (NASDAQ:JD) on Tuesday, November 14 to “Equal-Weight” rating. The stock of JD.Com Inc(ADR) (NASDAQ:JD) has “Buy” rating given on Tuesday, September 26 by Wells Fargo. The stock of JD.Com Inc(ADR) (NASDAQ:JD) has “Buy” rating given on Wednesday, August 23 by M Partners. TH Capital initiated the stock with “Buy” rating in Tuesday, August 4 report. On Friday, November 6 the stock rating was initiated by Goldman Sachs with “Buy”. The firm has “Overweight” rating given on Monday, January 9 by JP Morgan.Analysts await Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings on February, 27. They expect $-1.52 EPS, down 60.00% or $0.57 from last year’s $-0.95 per share. After $-1.41 actual EPS reported by Portola Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 7.80% negative EPS growth. Temasek Holdings Private Ltd, which manages about $15.51 billion US Long portfolio, upped its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 51,202 shares to 177,553 shares, valued at $87.20M in 2017Q2, according to the filing. Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals had 28 analyst reports since August 5, 2015 according to SRatingsIntel. On Monday, June 26 the stock rating was maintained by Oppenheimer with “Buy”. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 5. The rating was maintained by Citigroup with “Buy” on Friday, May 27. The stock has “Buy” rating by Credit Suisse on Wednesday, September 20. Credit Suisse upgraded the stock to “Outperform” rating in Thursday, August 24 report. Credit Suisse maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Friday, August 19. Credit Suisse has “Neutral” rating and $25 target. The firm has “Buy” rating by Citigroup given on Tuesday, January 3. Oppenheimer maintained it with “Buy” rating and $8000 target in Thursday, August 10 report. As per Sunday, July 23, the company rating was maintained by Oppenheimer. Morgan Stanley maintained it with “Buy” rating and $7000 target in Monday, June 26 report.Investors sentiment decreased to 1.31 in Q2 2017. Its down 0.29, from 1.6 in 2017Q1. It worsened, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Fincl Bank Of Mellon Corp stated it has 277,642 shares. The Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Hall Laurie J Trustee has 190 shares. Fernwood Invest Ltd Liability Com has 238,877 shares. Atwood Palmer holds 0.01% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 1,000 shares. Invesco Limited owns 145,066 shares. Gp One Trading Limited Partnership holds 0.04% or 64,173 shares. Pacad Inv Ltd holds 27,590 shares. Deutsche Bank Ag holds 626,798 shares or 0.03% of its portfolio. Blair William & Il invested in 0.01% or 31,600 shares. Royal Financial Bank Of Canada stated it has 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Profund Advsrs reported 23,074 shares. Wexford Cap Limited Partnership accumulated 6,600 shares. Blue Jay Capital Lc invested 4.59% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Castleark Mgmt Limited Liability Corporation accumulated 42,286 shares.More notable recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Gurufocus.com which released: “Partner Fund Management, LP Buys Portola Pharmaceuticals Inc, Centene Corp …” on November 16, 2017, also Seekingalpha.com with their article: “Portola Pharmaceuticals’ (PTLA) CEO William Lis on Q3 2017 Results – Earnings …” published on November 07, 2017, Globenewswire.com published: “Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on …” on November 07, 2017. More interesting news about Portola Pharmaceuticals Inc (NASDAQ:PTLA) were released by: Globenewswire.com and their article: “Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and …” published on October 30, 2017 as well as Globenewswire.com‘s news article titled: “Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch” with publication date: November 21, 2017.Since May 31, 2017, it had 0 insider buys, and 1 insider sale for $58.48 million activity. $58.48M worth of Portola Pharmaceuticals Inc (NASDAQ:PTLA) was sold by Maxwell (Mauritius) Pte Ltd.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
TRADE IDEAS REVIEW – IS THIS THE BEST STOCK SCANNER?

Trade Ideas is arguably one of the top scanning tools available on the market right

Trade Ideas Pro helps traders find the best setups in the market right NOW

Scottrade and E*TRADE license Trade Ideas proprietary technology for their premium trading platforms. We have fully automated trading available through Lightspeed and Interactive Brokers.Trade Ideas is the BEST Tool for Scanning. I would be LOST without Trade ideas. Ross Cameron – Warrior Trading